Syngene
Syngene International Limited, commonly referred to as Syngene, is a leading global contract research and manufacturing organisation headquartered in Bengaluru, India. Founded in 1993, Syngene has established itself as a key player in the biopharmaceutical industry, providing integrated research and development services to clients across the globe. With a strong presence in North America, Europe, and Asia, Syngene offers a diverse range of services, including drug discovery, development, and manufacturing. The company is renowned for its innovative approach, leveraging cutting-edge technologies to deliver high-quality solutions tailored to client needs. Syngene's commitment to excellence has earned it a prominent market position, with notable achievements in collaborations with major pharmaceutical companies. Its unique blend of scientific expertise and operational efficiency sets Syngene apart in the competitive landscape of life sciences.
DitchCarbon Score
How does Syngene's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Syngene's score of 70 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Syngene's reported carbon emissions
In 2024, Syngene International Limited reported total carbon emissions of approximately 66,530,000 kg CO2e for Scope 1, 12,961,000 kg CO2e for Scope 2 (market-based), and 48,780,000 kg CO2e for Scope 3 emissions. This reflects a significant increase in emissions compared to 2023, where Scope 1 emissions were about 6,003,000 kg CO2e, Scope 2 emissions (market-based) were approximately 18,765,000 kg CO2e, and Scope 3 emissions reached about 89,418,000 kg CO2e. Syngene has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 54.6% by FY2033, using FY2023 as the baseline. Additionally, the company plans to ensure that 81.6% of its suppliers, covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by FY2028. In the near term, Syngene aims to reduce its Scope 1 emissions by 30% and Scope 2 emissions by 25% from a 2021 baseline by 2030. The company is actively engaging with its tier 1 suppliers to achieve emissions reductions across its supply chain, demonstrating a commitment to sustainability and climate action. Overall, Syngene's initiatives align with industry standards for climate responsibility, reflecting a proactive approach to managing and reducing carbon emissions in the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 772,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 12,038,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Syngene is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
